DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages

Cutaneous effects of drugs of abuse

Authors: Anes Yang, Jaime Baquiran, Winston Kardell, Karen Fisher; Drug and Alcohol Department, Nepean Hospital, Sydney, NSW, Australia. DermNet NZ Editor-in-Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. April 2019.


What is drug abuse?

Abuse of addictive substances, including prescription medications, is a complex, serious issue which contributes to significant disease, injury, illness, violence, crime, social, community safety, and family issues [1]. Substance abuse disorders can vary between occasional hazardous use and severe disorders of dependency.

  • Cutaneous manifestations can be the earliest identifiable signs of substance abuse and related systemic diseases.
  • Substance abuse in patients with chronic disabling skin conditions can be in response to embarrassment and feelings of rejection, stigma, and low self-esteem, or as a means of relieving pruritus.

This review discusses alcohol, methamphetamine, cocaine, cannabis, illegal and pharmaceutical opiates, and commonly associated co-morbidities.

Drug use in Australia

According to the 2016 National Drug Strategy Household Survey (NDSHS), young adulthood (18–29 years) is a high-risk time for the use and misuse of licit and illicit substances, relative to other age groups. People living in remote and very remote areas were more likely to smoke, drink at harmful levels, and use cannabis and methamphetamines, but less likely to use illicit drugs such as cocaine and ecstasy compared with those in major cities.

In 2011, alcohol was responsible for 5.1% of the total burden of disease and injury in Australia, and illicit drug use contributed to 1.8% (AIHW 2016). This included the impact of injecting drug use, and cocaine, opioid, amphetamine, and cannabis dependence.

Alcohol

Alcohol abuse and dependence are common and the second highest cause of preventable drug-related hospitalisation and mortality in Australia. One study reported that 34.7% of patients who attend Australian public hospital outpatient departments were identified as having unhealthy levels of alcohol consumption [2]. The NDSHS reported a decline in daily alcohol consumption between 2013 (6.5%) and 2016 (5.9%). However, the proportion of people binge drinking did not change. Ninety per cent of Australians have had alcohol in their lifetime, with about a quarter drinking at levels associated with increased risk of long term harm [3].

Alcohol is a legal sedative-hypnotic class of drug that impairs motor function and coordination, decision-making, and judgement. It affects the nervous system through the facilitation of inhibitory pathways (GABA) and inhibition of excitatory pathways (NMDA) [4]. A careful history is required to elucidate alcohol consumption to determine alcohol misusers and alcohol dependency.

Every drink above two standard drinks a day increases the lifetime risk of disease and injury. Physical harms include direct physical injury from risk-taking behaviour, excessive sedation, inflammation of the gastrointestinal tract, alcoholic liver cirrhosis, pancreatic inflammation, nutritional deficiencies, cognitive impairment, rhythm and structural disorders of the heart, and altered immunity [5–7].

Cutaneous manifestations of chronic liver disease and cirrhosis associated with alcohol

Cutaneous changes can occur at any stage of alcohol abuse.

Classical stigmata of alcoholic liver disease and cirrhosis

Spider angioma

Superficial erythematous macule with radiating arterioles, classically on the hands, upper chest, neck and face due to alcohol-induced vasodilation and elevated oestrogen levels [8].

Facies alcoholica

Flushed face with telangiectasia on the face, cheek, ear lobes and nose due to loss of vasoreguatory control [8].

Caput medusa

Dilated peri-umbilical veins due to liver cirrhosis and portal hypertension.

Jaundice

Yellow discolouration of the skin and mucous membranes due to elevated serum bilirubin.

Scleral icterus

Yellowing of the sclera.

Nail changes

Leukonychia and platonychia.

Palmar erythema

Well-demarcated erythema, most prominent over the hypothenar eminence.

Pruritus

Commonly associated with long term use of alcohol, mainly if cholestasis is present due to alcohol-related liver disease.

Hyperpigmentation

Accentuation of freckling and areolar pigmentation or generalised brown-grey pigmentation in sun-exposed areas is due to acquired haemochromatosis, as alcohol facilitates the absorption of iron.

Haemorrhagic petechiae and ecchymoses

Due to acquired thrombocytopenia and vascular fragility.

Cutaneous changes due to nutrient and vitamin deficiencies with excessive alcohol

Malnutrition in those dependent on alcohol is multifactorial. The most common vitamin deficiency is vitamin B1 (thiamine), which presents as Wernicke-Korsakoff syndrome in the later stages of alcohol dependence [9].

Cutaneous changes in patients with vitamin deficiencies

Vitamin A

  • Xerosis
  • Follicular hyperkeratosis on the dorsal and lateral aspects of the extremities

Vitamin B1 (thiamine)

  • Wernicke-Korsakoff syndrome
  • Peripheral oedema
  • Red and thickened tongue

Vitamin B2 (riboflavin)

Vitamin B3 (niacin)

  • Pellagra
  • Symmetrical eruption of patches and plaques on sun-exposed areas
  • Xerotic, brittle skin
  • Cheilitis and glossitis

Vitamin B6

Vitamin C

  • Scurvy
  • Follicular hyperkeratosis with corkscrew hairs
  • Gingival oedema
  • Compromised wound healing

Zinc

Psoriasis

There is a complicated relationship between alcohol consumption and psoriasis. Two patterns have been identified in patients who misuse alcohol.

  • Flat hyperkeratotic, erythematous plaques over the acral surfaces.
  • Inflammatory plaques with minimal scale involving the face, groin, and flexures.

Porphyria cutanea tarda

Porphyria cutanea tarda results from a complex interaction between inherited and acquired factors, including alcohol-induced liver damage. It presents as hemorrhagic bullae, crusting and scarring in sun-exposed areas due to a defect in uroporphyrinogen decarboxylase. This leads to the accumulation of porphyrins that cause photosensitivity.

Rosacea

A variety of factors are responsible for the different presentations of rosacea (flushing, papules and pustules, rhinophyma, and tissue hyperplasia) [10].

  • Alcohol causes erythema and flushing due to cutaneous vasodilation and pro-inflammatory effects.
  • A large cohort study demonstrated that alcohol intake (especially white wine or liquor) is significantly associated with an increased risk of rosacea in women in a dose-dependent manner [11].
  • Collagen III propeptide is increased in patients with high alcohol consumption, providing a clue to the mechanism of tissue hyperplasia in late-stage rosacea [12].

Discoid eczema

Localised and well-demarcated plaques of acute exudative discoid eczema on the shins of middle-aged men can indicate alcohol misuse [13].

Increased skin infections

Alcohol-induced immune dysfunction facilitates colonisation by commensal organisms and an increased incidence of cutaneous infections [14].

Seborrheic dermatitis

There is a very strong association between the incidence and severity of seborrhoeic dermatitis and alcohol consumption [14].

Cancer

High intake of alcohol is associated with squamous cell carcinoma of the skin, mouth, and oropharynx, as well as hepatocellular carcinoma, pancreatic carcinoma, and breast cancer in women [13]. Basal cell carcinomas may be more aggressive, more likely to be infiltrative, and exhibit a higher incidence of local recurrence [3].

Methamphetamine

Methamphetamine, also known as meth or ice, is manufactured from pseudoephedrine, ephedrine, acetone, ammonia, and ethylene glycol. Crystal methamphetamine is now the third most common illicit substance used in Australia, after cannabis and cocaine [15]. Its use increased from 22% of recent meth/amphetamine users in 2010 to 57% in 2016. The overall use of ice across the population rose from 0.4% in 2010 to 0.8% in 2016, with over 200,000 current users in 2015. Over half of those who use methamphetamine meet criteria for dependent use [16].

Methamphetamine is commonly smoked, injected, or snorted. It is a sympathomimetic agonist that acts centrally to release dopamine and other biogenic monoamines from their storage sites in the nerve terminals to produce rapid euphoria, central nervous system (CNS), cardiovascular, and smooth muscle effects. Immediate effects include increased energy, concentration, tachycardia, fluctuant blood pressure, hyperhidrosis, mydriasis, bruxism, generalised pruritus, xerosis, and compulsive skin picking [17].

Prolonged use results in:

  • Cardiovascular effects including hypertension, tachycardia, and direct myocardial toxicity resulting in arrhythmias, malignant hypertension, haemorrhagic stroke, cardiac ischaemia, cardiomyopathies, and right heart failure [18]
  • Mood disorders, psychosis, cognitive impairment, and cortical grey matter loss [19]
  • Malnutrition, weight loss, and premature ageing
  • Dental decay, due to a combination of vasoconstriction, poor dental hygiene, consumption of high-calorie sugar drinks, and xerostomia [20,21]
  • Neurotic excoriations and abscess, most commonly on limbs [22].

Cocaine

Cocaine is also known as rack, blow, Charlie, coke, snow, or flake is a sympathomimetic that causes feelings of euphoria, increased confidence, and well-being. Cocaine is extracted from the Erythroxylum coca plant into a water-soluble powder that is usually inhaled (snorted), ingested, or injected. Its short-term effects include tachycardia, hypertension, altered mental status, and mydriasis [23,24].

The use of cocaine in Australia has increased from 1.3% in 2001 to 2.5% in 2016. It is the second most commonly used illegal drug after cannabis [16]. Australians are the world’s eighth-highest per capita users of cocaine. Nine per cent of Australians aged 14 years and over have used cocaine one or more times in their life, and its use is increasing with casual users as well as dependent and frequent users [1,3].

Cutaneous effects include:

Many adverse effects in relation to cocaine use are linked to ‘expanders’ or cutting agents that are mixed with cocaine to increase profitability for dealers [27]. According to the 2015 Illicit Drug Reporting System, the purity of cocaine seized in Australia ranged between 29.9% and 64.5%, and in Sydney, between 9% and 40% [28]. Common adulterants and cutting agents include talc, mannitol, glass, starch, quinine, lignocaine, amphetamine, caffeine, heroin, scopolamine, hydroxyzine, diphenhydramine, and levamisole [26].

Levamisole has been identified in Australian street cocaine, and unlike other cutting agents, it is added at the onset of manufacturing. Levamisole potentiates the effects of cocaine and increases dopamine levels. It is an antiparasitic medication used for livestock and was removed from human therapeutic use due to neutropenia, agranulocytosis, and vasculitis. Vasculitis from cocaine mixed with levamisole presents as distinct purpuric lesions involving the external pinna and cheeks [28].

Cannabis

Cannabis is a psychoactive drug from the dried buds and flowers of the Cannabis sativa plant. In Australia, it is also known as ganja, yarndi, weed, and dope. Cannabis is usually smoked in hand-rolled cigarettes (a ‘joint’) or a water-pipe (a ‘bong’). Cannabis can also be added to foods for consumption. It is the most common illicit drug in Australia, with over one-third of Australians aged 14 years and over having had used cannabis at least once in their lifetime [15].

Its psychoactive properties are derived from the chemical compound delta-9-tetrahydrocannabinol (THC) among other compounds that target cannabinoid receptors in the brain to produce euphoria and heightened senses. This activation of the cannabinoid receptors leads to a reduction in nitric oxide that causes systemic vasoconstriction.

Non-psychotropic phytocannabinoids derived from Cannabis sativa have demonstrated sebostatic, anti-inflammatory and antiproliferative mechanisms and have pharmacological potential in the treatment of acne, pruritus, various inflammatory skin diseases, and skin cancer [32].

Opioids

Pharmaceutical opioid-related deaths, overdoses, and emergency presentations exceed those related to illicit heroin [1].

Drugs of the opioid class can either be naturally occurring, or synthetic. The actions of these substances are mediated through agonism of mu, kappa, and delta-opioid receptors [33].

  • Pharmaceutical opioids include morphine, hydromorphone, codeine, fentanyl, and oxycodone.
  • They are usually ingested orally or crushed and snorted intranasally or dissolved and injected intravenously.
  • Tolerance and physical dependence develop upon repeated administration of opiate medications with a high potential for abuse and the development of a strong physiological dependence.
  • Long-acting opioids such as methadone and buprenorphine improve outcomes in patients with opioid dependence.

Acute opioid toxicity results in stupor and respiratory depression.

  • Chronic use of opioids can cause orthostatic hypotension, nausea and vomiting, constipation, and potential faecal impaction.
  • Long-acting opioids have been implicated in causing central sleep apnoea.
  • High doses of methadone are associated with prolonged QT and subsequent risk of torsades de pointes.
  • Opioids influence the hypothalamic-pituitary-adrenal or gonadal axes. This can result in an increase in serum prolactin and a decrease in plasma cortisol and testosterone (male hypogonadism) [34].

Dermatological manifestations of opioid use may include:

The symptoms of opioid withdrawal resemble a 'flu-like illness with myalgia, rhinorrhoea, nausea and vomiting, lacrimation, piloerection, insomnia, dilated pupils, irritability, low-grade fever, and tachycardia [33].

Injection-related cutaneous signs

Track marks at injection sites present as linear postinflammatory hyperpigmentation, most commonly observed in the antecubital fossa of the non-dominant arm. Other common injection sites include the veins of the dorsum of the hands and feet, forearm, popliteal fossa, inguinal fold, neck, and penis [26,35,36].

  • Tattoos may be used to conceal the track marks.
  • Over time, the injection sites become thickened, sclerosed, and inaccessible.
  • Some drug users resort to intradermal, subcutaneous, or even intramuscular drug administration (‘skin popping’) resulting in irregular, white, deep circular, punched-out atrophic scars [35].
  • Foreign body granulomas can form at the injection site due to additives such as plastic, glass, talcum, mannitol, starch, or flour [37].

Vascular complications may include:

  • Superficial thrombophlebitis and deep venous thrombosis
  • Chronic venous insufficiency including peripheral oedema and venous stasis dermatitis
  • Arterial insufficiency, necrosis, thromboembolism, and compartment syndrome due to accidental or purposeful arterial injections  [35,36].

Skin and soft tissue infections

Drugs of various types may be dissolved in tap water by a drug abuser, drawn into a syringe and injected into a vein or skin. Infectious complications of non-sterile injection include abscess, cellulitis, and erysipelas. Contributing factors are:

  • The contamination of drug with expedients
  • The use of non-sterile water, needles, or equipment
  • The re-use of needles
  • Skin popping — this carries a five-fold risk of infection compared to intravenous injection resulting in a multilobulated, deep and necrotic abscess [37]
  • Immunosuppression due to blood-borne viruses (such as human immunodeficiency virus, HIV)
  • Malnutrition
  • The specific drug — infection is especially likely when injecting a mixture of heroin and cocaine, known as ‘speedball’.

Skin and soft tissue infections are often multibacterial and due to commensal pathogens, commonly Staphylococcus aureus, Streptococcus milleri and alpha-haemolytic streptococci. The practice of licking or blowing out the injection needle before injection increases the risk of infection with resident oral flora, gram-negative bacteria (Pseudomonas aeruginosa, Escherichia coli, Enterobacter cloacae, Proteus vulgaris, Klebsiella, Haemophilus) and anaerobic species (Bacteroides, Fusobacterium, Eikenella corrodens) [38]. Patients present with large indurated abscesses.

Most patients with injection-site infections have normal inflammatory markers and negative blood cultures.

Other infections

People who misuse substances are at an increased risk of blood-borne infectious diseases such as HIV, hepatitis B, and hepatitis C, and sexually transmissible infections such as syphilis, gonorrhoea, infections with Chlamydia trachomatis (lymphogranuloma venereum), Trichomonas vaginalis (trichomoniasis) and Herpes simplex 1 and 2 [39].

Scabies, tinea, and impetigo contagiosa are frequently observed in those who are homeless or living in situations of neglect. Clinicians should also be mindful of signs and symptoms of endocarditis.

See smartphone apps to check your skin.
[Sponsored content]

 

Related information

 

References

  1. NDS. National Pharmaceutical Drug Misuse Framework for Action. Canberra; 2015.
  2. Johnson NA, Kypri K, Latter J, McElduff P, Saunders JB, Saitz R, et al. Prevalence of unhealthy alcohol use in hospital outpatients. Drug Alcohol Depend 2014; 144: 270–3. doi: 10.1016/j.drugalcdep.2014.08.014. PubMed
  3. AIHW. National Drug Strategy Household Survey 2016: detailed findings. Drug Statistics series no. 31. Cat. no. PHE 214. Canberra; 2017. Available from: www.aihw.gov.au/getmedia/15db8c15-7062-4cde-bfa4-3c2079f30af3/21028a.pdf.aspx?inline=true (accessed 28 April 2020).
  4. Bruno Ridolfo CS. The quantification of drug-caused mortality and morbidity in Australia, 1998. In: Welfare AIoHa, editor. Canberra: AIHW (Drug Statistics Series no. 7); 2001.
  5. NHMRC. Australian guidelines to reduce health risks from drinking alcohol. Canberra: National Health and Medical Research Council; 2009.
  6. Corrao G, Bagnardi V, Zambon A, Arico S. Exploring the dose‐response relationship between alcohol consumption and the risk of several alcohol‐related conditions: a meta‐analysis. Addiction 1999; 94: 1551–73. PubMed
  7. Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004; 38: 613–9. PubMed
  8. Umulis DM, Gurmen NM, Singh P, Fogler HS. A physiologically based model for ethanol and acetaldehyde metabolism in human beings. Alcohol 2005; 35: 3–12. PubMed
  9. Lieber CS. Relationships between nutrition, alcohol use, and liver disease. Alcohol Res Health 2003; 27: 220–31. PubMed
  10. Higgins E, du Vivier A. Alcohol intake and other skin disorders. Clin Dermatol 1999; 17: 437–41. PubMed
  11. Li S, Cho E, Drucker AM, Qureshi AA, Li WQ. Alcohol intake and risk of rosacea in US women. J Am Acad Dermatol 2017; 76: 1061–7.e2. doi: 10.1016/j.jaad.2017.02.040. PubMed Central
  12. Wilkin JK. The red face: flushing disorders. Clin Dermatol 1993; 11: 211–23. PubMed
  13. Higgins EM, Vivier AWPd. Cutaneous disease and alcohol misuse. Br Med Bull 1994; 50: 85–98. PubMed
  14. Parish L, Fine E. Alcoholism and Skin Disease. Int J Dermatol 1985; 24: 300–1. PubMed
  15. Oram Y, Orengo I, Griego RD, Rosen T, Thornby J. Histologic patterns of basal cell carcinoma based upon patient immunostatus. Dermatol Surg 1995; 21: 611–4. PubMed
  16. Degenhardt L, Larney S, Chan G, Dobbins T, Weier M, Roxburgh A, et al. Estimating the number of regular and dependent methamphetamine users in Australia, 2002–2014. Med J Aus 2016; 204: 153. Journal
  17. Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman's the pharmacological basis of therapeutics. 2011.
  18. Paratz ED, Cunningham NJ, MacIsaac AI. The cardiac complications of methamphetamines. Heart Lung Circ 2016; 25: 325–32. PubMed
  19. Nakama H, Chang L, Fein G, Shimotsu R, Jiang CS, Ernst T. Methamphetamine users show greater than normal age-related cortical gray matter loss. Addiction 2011; 106: 1474–83. PubMed
  20. Marshall BD, Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction 2010; 105: 991–1002. PubMed
  21. Hamamoto D, Rhodus N. Methamphetamine abuse and dentistry. Oral Dis 2009; 15: 27–37. PubMed
  22. Rusyniak DE. Neurologic manifestations of chronic methamphetamine abuse. Neurol Clin 2011; 29: 641–55. PubMed
  23. Brewer JD, Meves A, Bostwick JM, Hamacher KL, Pittelkow MR. Cocaine abuse: dermatologic manifestations and therapeutic approaches. J Am Acad Dermatol 2008; 59: 483–7. PubMed
  24. Belin D, Mar AC, Dalley JW, Robbins TW, Everitt BJ. High impulsivity predicts the switch to compulsive cocaine-taking. Science 2008; 320: 1352–5. PubMed
  25. Gontijo B, Bittencourt FV, Lourenço LFS. Skin manifestations of illicit drug use. Anais Brasileiros de Dermatologia 2006; 81: 307–17. Journal
  26. Hennings C, Miller J. Illicit drugs: What dermatologists need to know. J Am Acad Dermatol 2013; 69: 135–42. PubMed
  27. Stafford J, Breen C. Australian Drug Trends 2015 Findings from the Illicit Drug Reporting System (IDRS) Australian Drug Trends Series No. 145. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2015. Available from: https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/AUSTRALIAN_IDRS_2015_0.pdf (accessed 24 April 2020)
  28. Jacob RS, Silva CY, Powers JG, Schieke SM, Mendese G, Burlingame RW, et al. Levamisole-induced vasculopathy: a report of 2 cases and a novel histopathologic finding. Am J Dermatopathol 2012; 34: 208–13. doi: 10.1097/DAD.0b013e31821cc0bf. PubMed
  29. Peyrot I, Garsaud AM, Saint-Cyr I, Quitman O, Sanchez B, Quist D. Cannabis arteritis: a new case report and a review of literature. J Eur Acad Dermatol Venereol 2007; 21: 388–91. PubMed
  30. Santos RP, Resende CI, Vieira AP, Brito C. Cannabis arteritis: ever more important to consider. BMJ Case Rep 2017. doi: 10.1136/bcr-2016-219111. PubMed
  31. Raiker N, Aouthmany M, Ezra N. Dermatologic Signs and Symptoms of Substance Abuse. 2016. Journal
  32. Gurbir D, Mark GK. The Risks and Benefits of Cannabis in the Dermatology Clinic. J Cutan Med Surg 2018; 22: 194–9. doi: 10.1177/1203475417738971. PubMed
  33. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008; 11: S133–53. PubMed
  34. Ricardo Buenaventura M, Rajive Adlaka M, Nalini Sehgal M. Opioid complications and side effects. Pain Physician 2008; 11: S105–S20. PubMed
  35. Fink B, Landthaler M, Hafner C. Skin alterations due to illegal drug abuse. J Dtsch Dermatol Ges 2011; 9: 633–8; quiz 639. PubMed
  36. Brown PD, Ebright JR. Skin and Soft Tissue Infections in Injection Drug Users. Curr Infect Dis Rep 2002; 4: 415–9. PubMed
  37. Lloyd-Smith E, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T. Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health 2008; 8: 405. doi: 10.1186/1471-2458-8-405. PubMed
  38. Gordon RJ, Lowy FD. Bacterial infections in drug users. New Engl J Med 2005; 353: 1945–54. PubMed
  39. Sanchez MR. Alcohol, social behavior disorders, and their cutaneous manifestations. Clin Dermatol 1999; 17: 479–89. PubMed

On DermNet NZ

Books about the skin